<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02420158</url>
  </required_header>
  <id_info>
    <org_study_id>2014.844</org_study_id>
    <nct_id>NCT02420158</nct_id>
  </id_info>
  <brief_title>Trans-cutaneous Vagal Nerve Electrical Stimulation and Irritable Bowel Syndrome</brief_title>
  <acronym>StVSII</acronym>
  <official_title>Sympatho-vagal Balance in Patients With Irritable Bowel Syndrome, and Evaluation of a Transcutaneous Vagal Nerve Electrical Stimulation on Symptoms and Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study plan to investigate the sympathovagal balance in women affected by Irritable
      Bowel Syndrome (IBS), and to evaluate the effect of 6 months of trans-cutaneous vagal nerve
      electrical stimulation on digestive physiology (intestinal transit time, intestinal mucosal
      permeability, systemic and local inflammation), symptoms and quality of life.

      The safety of the electrical stimulation of the left vagal nerve will also be evaluated.

      Ten women, age between 18 and 60, will be included.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of clinical symptoms of IBS, based on the evolution of symptom score (Francis) and symptom scale (UCLA-SSS)</measure>
    <time_frame>3 and 6 months after the beginning of electrical stimulation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerance of trans-cutaneous nerve stimulation as measured by any symptom occurring in relation with electrical stimulation, number of hours per day of system use</measure>
    <time_frame>6 months</time_frame>
    <description>Any symptom occurring in relation with electrical stimulation, number of hours per day of system use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of digestive physiology during vagal nerve stimulation</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Digestive physiology is evaluated by intestinal transit time with Smartpill capsule, lactuose/mannitol intestinal permeability test, fecal calprotectin and blood cytokines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of vagal nerve stimulation on quality of life</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Quality of life and psychological questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of sympatho-vagal balance</measure>
    <time_frame>0, 3 and 6 months</time_frame>
    <description>Measurement by nocturnal EKG Holter of the variability of the interval RR, as a marker of the sympatho-vagal balance</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Vagal nerve stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trans-cutaneous vagal nerve electrical stimulation during 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Trans-cutaneous vagal nerve electrical stimulation</intervention_name>
    <arm_group_label>Vagal nerve stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women aged 18-60,

          -  clinical Rome III criteria for IBS

        Exclusion Criteria:

          -  pregnancy,

          -  low intensity symptoms (Francis score between 75-150)

          -  IBD, coeliac disease

          -  past history of abdominal surgery (appendectomy and cholecystectomy allowed)

          -  chronic use of analgesics, anti-depressants
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François MION, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Universitaire d'Hépato-Gastroentérologie - CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Exploration Fonctionnelle Digestive - Hôpital Edouard Herriot - Hospices Civils de Lyon</name>
      <address>
        <city>LYON Cedex 03</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>April 14, 2015</study_first_submitted>
  <study_first_submitted_qc>April 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2015</study_first_posted>
  <last_update_submitted>January 3, 2019</last_update_submitted>
  <last_update_submitted_qc>January 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>Vagal nerve stimulation</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

